Articles In Press                   Back to the articles list | Back to browse issues page

XML Print


1- Department of interventional cardiology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
2- Cardiologist, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. , M_bekravi@yahoo.com
Abstract:   (21 Views)
Hypereosinophilic syndrome (HES) characterized by persistent eosinophilia without any discernible underlying cause. The patient might exhibit no symptoms at all or may manifest a disorder affecting multiple systems.  Electrocardiography, echocardiography and cardiac magnetic resonance imaging are commonly used methods to assess cardiac involvement in HES. Recognizing HES early can be difficult since the initial stage typically lacks noticeable clinical symptoms. Here, we report a 45-years-old man with HES which mimics the acute coronary syndrome signs and symptoms, after ruling out other possible diagnoses, Electrocardiography revealed inverted T-waves in pericardial leads (V4–V6). Coronary angiography demonstrated non-obstructive coronary artery disease. Echocardiography showed moderate left ventricular (LV) hypertrophy, a lobulated apical LV mass, trivial tricuspid regurgitation, and mild pleural effusion. Cardiac MRI identified an apical LV mass with iso/high signal intensity on STIR sequences and no enhancement on late gadolinium enhancement (LGE), consistent with LV thrombus in the setting of HES. On admission, troponin level was 869 ng/ml. HES was confirmed and the patient was treated with prednisolone (5 mg/kg daily) and apixaban (10 mg BID for 7 days, then 5 mg BID). Follow-up demonstrated a decrease in troponin to 351 ng/ml and complete resolution of the LV thrombus on echocardiography.
 
     
Type of Study: Case Report Article | Subject: Clinical Medicine
Received: 2025/06/10 | Accepted: 2026/06/22

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.